Medcura Taps J&J Veteran to Steer Breakthrough Gel to Market

RIVERDALE, MD – May 01, 2026 – Medcura, Inc. has made a significant strategic move in its quest to disrupt the multi-billion-dollar surgical bleeding market, appointing medical device industry titan Gary P. Fischetti to its Board of Directors. The appointment signals the company's aggressive push to commercialize its flagship product, LifeGel™, an absorbable hemostatic agent that has already garnered significant attention from regulators and clinicians.

Fischetti, whose career includes over three decades in senior leadership at Johnson & Johnson, joins Medcura as the company prepares to navigate the complex path from promising pre-clinical data to full-scale human trials and market entry. His extensive background in the very markets Medcura aims to penetrate—specifically in biosurgery and spine—is seen as a critical asset.

"We are thrilled to welcome Gary to Medcura's Board," said Jim Buck, Chief Executive Officer of Medcura. "With his proven leadership at Ethicon Biosurgery and DePuy Spine, Gary brings unmatched expertise in innovation, regulatory strategy, and global commercialization. His guidance will be invaluable as we advance LifeGel™ through pivotal pre-clinical studies and into human clinical trials."

For his part, Fischetti pointed to the unique potential of Medcura's technology as his reason for joining. "LifeGel™ stands out with its unique no-swell properties and is the first and only absorbable hemostatic agent to receive FDA Breakthrough Device designation," he stated. "Medcura's innovative and versatile hemostasis platform is well positioned to disrupt the entire surgical hemostasis market... which is ripe for transformational innovation."

A Strategic Play in a High-Stakes Market

The appointment of Gary Fischetti is more than a routine board addition; it is a clear statement of intent. Fischetti's 35-year tenure at Johnson & Johnson saw him rise to the highest echelons of the medical device world. He served as Company Group Chairman for North America Medical Devices, overseeing all 12 of the conglomerate's device businesses. Crucially for Medcura, he was also Worldwide President of DePuy Spine and held leadership roles at Ethicon, a dominant player in the surgical biosurgery space.

This experience provides Medcura with a director who has not only built and scaled businesses in their target market but has also competed against the very products LifeGel™ seeks to displace. His expertise in global commercialization and navigating complex regulatory landscapes is precisely what a company at Medcura's stage requires as it transitions from a development-focused entity to a commercial powerhouse. Fischetti’s continued influence is evident in his current roles as Chairman of the Board for Orchid Orthopedic Solutions and a board member at Anika Therapeutics and Acuitive Technologies, keeping him at the forefront of orthopedic and medical technology innovation.

The Promise of a No-Swell Solution

At the heart of Medcura's strategy is LifeGel™, a product born from a proprietary biopolymer platform. The global surgical hemostats market, valued at over $4 billion, is crowded with established products from giants like Baxter, B. Braun, and Fischetti's former employer, Ethicon. These products, including gelatin-based foams and oxidized cellulose fabrics, are designed to control bleeding during surgery. However, many come with a significant drawback: they swell as they absorb blood.

In most surgical fields, this swelling is manageable. But in confined spaces, such as during spinal surgery, it can be catastrophic. Swelling hemostatic agents used near the spinal cord can cause compression, leading to severe neurological damage, including paralysis. This well-documented risk has created a significant unmet clinical need for an effective, absorbable hemostat that does not expand.

This is where LifeGel™ aims to carve its niche. Its primary differentiating feature is its "no-swell" property. This unique characteristic was instrumental in the U.S. Food and Drug Administration granting it Breakthrough Device Designation in late 2022. This designation is reserved for innovative technologies that have the potential to provide more effective treatment for life-threatening or irreversibly debilitating conditions. It provides Medcura with a more collaborative and expedited review process with the FDA, potentially accelerating its path to patients.

Beyond its core property, LifeGel™ is being developed as a ready-to-use product, eliminating the often-burdensome preparation steps required for competing agents. The company is also developing it to be bacteria-resistant and to offer cost advantages, which could make it an attractive option for hospital purchasers navigating tight budgets.

Navigating the Path to Commercialization

Despite the promising technology and a fortified board, Medcura's journey is far from over. The surgical hemostasis market is projected to grow to over $7 billion by 2034, and capturing a piece of that pie requires navigating a gauntlet of clinical, regulatory, and commercial hurdles.

With $87.3 million raised over six funding rounds, Medcura is well-capitalized to take its next steps. The immediate focus is on completing pivotal pre-clinical testing and filing an Investigational Device Exemption (IDE) with the FDA. This filing is the gateway to initiating human clinical trials, a critical and costly phase designed to prove the safety and efficacy of LifeGel™ in its lead indication: spinal surgery, a segment that accounts for nearly two-thirds of the flowable gel market.

Bringing a veteran like Fischetti on board at this juncture provides invaluable strategic foresight. His deep understanding of the clinical data required, the regulatory pathways to be navigated, and the commercial strategies needed to unseat incumbent products will be essential. As Medcura prepares to go head-to-head with industry giants, having a leader who intimately knows the competitive playbook could be its most powerful asset in transforming the management of surgical bleeding.